The major involvement of chemokines and proteolytic enzymes has recently been discovered in the mobilization process. Here, we report that the degradation of BM stromal cell-derived factor (SDF-1) by matrix metalloproteinase (MMP)-9 is important in G-CSF-mediated hematopoietic stem/progenitor cells (HSPCs) mobilization. In this study, the SDF-1 concentration in healthy donors BM plasma decreased significantly after 5 days of G-CSF administration, with no obvious change of SDF-1 in the peripheral blood. We also observed a similar result by immunohistochemical staining on the BM biopsy slides. In vitro, mobilized BM plasma exhibited decreased chemotactic effect on CD34 þ cells, compared with steady-state BM plasma. MMP-9 protein and mRNA increased dramatically in the BM plasma in accordance with SDF-1 decrease. MMP-9 enriched supernatant from HT1080 cell-conditioned medium upregulated CXCR4 expression and the migration of BM CD34 þ cells toward SDF-1. SDF-1 was a substrate for MMP-9, furthermore, SDF-1 also stimulated MMP-9 proteolytic enzyme activity of BM CD34 þ cells, which facilitate HSPCs migration. In BALB/c mice, HSPCs mobilization was significantly inhibited by anti-SDF-1 antibodies or MMP inhibitor, o-phenanthroline. In conclusion, the degradation of BM SDF-1 by MMP-9 is a vital step in mobilization.
Introduction
Under normal conditions, most hematopoietic stem and progenitor cells (HSPCs) reside in the BM microenvironment and only a few HSPCs circulate in the peripheral blood (PB). 1 Hematopoietic growth factors, chemotherapeutics and chemokines can recruit HSPCs from BM into the circulation. 2 Currently, G-CSF has been proven to be the widest clinically used agent in eliciting mobilized HSPCs for transplantation, due to its substantial advantages, such as rapid hematopoietic reconstitution in the recipients, low risk of tumor cells contamination, easy acceptance by the donor. 3, 4 It is the prerequisite for successful PBSCT to mobilize and collect adequate HSPCs. Therefore, better understanding of the mechanisms of G-CSF-induced mobilization can improve transplantation outcomes.
Although the mechanisms underlying this process are incompletely defined, compelling evidence from genetargeting studies and other observations indicates that the chemokine receptor CXCR4 and its unique ligand stromal cell-derived factor 1 (SDF-1) play a critical role in the retention of HSPCs within BM and their mobilization to PB, especially in transmigration of HSPCs through the BM endothelium. 3, [5] [6] [7] [8] Elevation of SDF-1 in the blood by injection of an adenoviral vector expressing SDF-1 mediates a significant HSPC mobilization. 6 During the mobilization by G-CSF, SDF-1 protein and mRNA expression decreased in the BM. 3, 8, 9 The functional decrease in SDF-1 protein in BM is sufficient to mediate HSPCs migration into the blood circulation. 3 More importantly, the clinical efficacy of AMD3100, a CXCR4 antagonist, in mobilizing HSPCs either on its own or by potentiating the effect of G-CSF provides further evidence of the importance of this pathway in humans. [10] [11] [12] Collectively, these data suggest that SDF-1 functional degradation leading to the SDF-1 gradient disappearance between BM and PB is a key step in G-CSF-induced mobilization. However, G-CSF cannot induce SDF-1 decrease directly. The mechanisms behind the G-CSF-induced SDF-1 protein expression decrease in the BM have not been defined.
It had also been revealed that a highly proteolytic microenvironment was induced in the BM during G-CSF administration. In particular, matrix metalloproteinase (MMP)-9, neutrophil elastase (NE) and cathepsin G are thought to degrade key substrates including vascular cell adhesion molecule-1, SDF-1 and CXCR4. [13] [14] [15] In vitro, SDF-1 is cleaved or degraded to a nonfunctional chemokine by lymphocyte-associated cathepsin G, 16 NE 3 and MMPs (including MMP-2 and MMP-9).
17 MMP-9 is stored in gelatinase granules and CD34 þ progenitor cells, which can be rapidly released following activation. 18 It was reported that HSPC mobilization by G-CSF was significantly impaired in MMP-9-deficient mice, 19 suggesting that MMP-9 may be a major mediator of this process. However, recent data showed that HSPC mobilization mediated by G-CSF was normal in MMP-9-deficient mice. 20, 21 These inconsistent data promote us to further explore the role of MMP-9 in G-CSF-induced mobilization and the interaction with SDF-1.
In the present study, we performed a series of in vitro and in vivo experiments, and human and murine data revealed that MMP-9-dependent degradation of SDF-1 contributed to G-CSF-induced HSPC mobilization.
Materials and methods
Healthy donors and sample collection Plasma samples, PB and BM were obtained before (steady state, ssPB or ssBM) or 4-6 h after five days of human recombinant G-CSF (300 mg, b.i.d.; Kirin, Japan) administration (mobilized, mPB or mBM), with informed consent from healthy donors undergoing mobilization for allogeneic transplantation. The BM aspiration was performed by the same physician to reduce the variation of dilution by PB. Plasma samples were collected by two successive centrifugations (first at 1000 g for 15 min, and second at 10 000 g for 10 min) to achieve complete platelet removal and were stored at À80 1C for assay. Low-density mononuclear cells from BM and PB were separated by FicollHypaque. In addition, nucleated cells were obtained by removing RBCs with NH 4 Cl for MMP-9 mRNA assay. Enrichment of CD34
þ cells was performed with the miniMACS separation system (Miltenyi Biotech, Bergisch Gladbach, Germany) according to the manufacturer's instructions.
Human samples were used in accordance with approved procedures by the human experimentation and ethics committee of the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union of Medical College (PUMC).
Cell-conditioned medium
Human Fibrosarcoma HT-1080 cells known to secrete MMP-9 22 were incubated at a density of 2 Â 10 6 per ml in Iscove's modified Dulbecco's media (IMDM) without serum at 37 1C and 5% CO 2 for 24 h. The cell-conditioned medium (supernatants) of HT1080 cells were then collected and stored at À80 1C for further use.
Measurement of SDF-1 and MMP-9 plasma level Plasma levels of SDF-1 and MMP-9 from healthy donors samples were tested with human SDF-1a and MMP-9 immunoassay kits (R&D systems Inc., Minneapolis, MN, USA) by enzyme-linked immunosorbent assay (ELISA) as per the manufacturer's instructions. The concentrations of SDF-1a and total MMP-9 for each sample were calculated based on the average of different dilutions and experiments were repeated three times.
Immunohistology of BM sections of healthy donors
Immunohistochemical staining was performed on formalinfixed, paraffin-embedded human BM sections as described previously. 23 Anti-human SDF-1 MoAb (clone: 79018; R&D systems) and anti-MMP-9 MoAb (clone: 4H3; R&D systems) were employed using the streptavidin-peroxidase method. The concentration of primary antibodies was 16 mg/ml (SDF-1) or 25 mg/ml (MMP-9).
SDF-1 and MMP-9 semiquantitative reverse transcription-PCR analysis Human umbilical vein endothelial cells (HUVECs) and stromal cells were prepared using the methods described previously. 24, 25 After starvation without serum for 6 h, cells were incubated with G-CSF at a concentration of 25 ng/ml for another 24 h at 37 1C and 5% CO 2 . Then cells were subjected to RT-PCR.
Oligonucleotide primers were used as follows: SDF-1 (251 bp):
0 . Each PCR cycle consisted of a heat-denaturation step at 95 1C for 45 s, a primer-annealing step at 55 1C for 45 s, and a strand-elongation step at 72 1C for 45 s. The amplification was performed for 30 cycles.
Chemotaxis assays
All assays were performed in triplicate using 5-mm pore transwell filters (24-well, cluster; Costar, Corning Inc., Lowell, MN, USA). The 100 ml chemotaxis buffer containing 1 Â 10 5 BM CD34 þ cells were added to the upper chamber and 600 ml of ssBM or mBM supernatant from healthy donors were added to the lower chamber. In other assays, 100 ng/ml human recombinant SDF-1 (BioSource International Inc., Camarillo, CA, USA) was added to the lower chamber, and CD34 þ cells were added into the upper chamber by preincubated with: (1) 1 mmol/l MMP inhibitor (Sigma-Aldrich, St Louis, MO, USA) alone. (2) HT1080-conditioned medium alone. (3) MMP inhibitor þ HT1080-conditioned medium for 30 min at 37 1C. After incubated at 37 1C in 5% CO 2 for 4 h, cells migrating into the lower chamber were counted using FACScalibur flow cytometer (number of migrated CD34 þ cells/number of total CD34 þ cells Â 100%).
Western blot
The degrading effect of MMP-9 on SDF-1 was assayed by western blot. Recombinant rhSDF-1a (50 ng, R&D Systems) was incubated for 4-6 h at 37 1C with MMP-9 (10 ng, R&D Systems) or with ssBM and mBM plasma from SDF-1 and MMP-9 on G-CSF-induced HSPC mobilization F Jin et al healthy donors (20 ml). Reactions were terminated by the addition of SDS-polyacrylamide gel electrophoresis (PAGE) loading buffer. Then the samples were electrophoresed in a 15% polyacrylamide gel and transferred onto polyvinylidene fluoride membrane (GIBCO, Shanghai, China) for 2 h with a semidry blotter (Bio-Rad, Foster City, CA, USA). After blocking with 5% nonfat milk overnight, the membranes were incubated with mouse anti-human SDF-1 MoAb (4 mg/ml) for 2 h, followed by 1:5000 dilution of horseradish peroxidade-anti-mouse (Sigma, Shanghai, China) for 1 h. The chemiluminescent signals were revealed by the addition of substrates.
Zymographic analysis and SDS-polyacrylamide gel electrophoresis MMP-9 activities were evaluated using SDS-PAGE. Briefly, BM CD34 þ cells were incubated at the concentration of 2.0 Â 10 6 per ml in serum-free IMDM in the presence and absence of 100 ng/ml human recombinant SDF-1 (BioSource International Inc.) or 25 ng/ml human recombinant G-CSF at 37 1C and 5% CO 2 for 24 h. The cell-conditioned medium was collected and analyzed. Conditioned medium of HT-1080 cells without serum was used as positive controls for zymographic analysis. Gelatinolytic activities were assessed using SDS-PAGE. Medium conditioned by HT1080 were used as the standard.
Flow cytometry analysis
The expression of CXCR4 on the CD34 þ cells before and after incubation with HT1080-conditioned medium or serum-free IMDM was determined by flow cytometry. Mobilization of hematopoietic cells in mice BALB/c mice (6-to 8-week old) from Institute of Laboratory Animal Science, CAMS and PUMC were divided into four groups (three mice per group). The first group received PBS for 5 days. The second group was treated by once daily s.c. injection of G-CSF at a dose of 250 mg/kg body weight (b.w.) per day for 5 consecutive days. The third group was administered i.p. injection of SDF-1 MoAb at 100 mg/kg b.w. per day on days 4 and 5 in combination with G-CSF 250 mg/kg b.w. per day. The fourth group was administered i.p. injections of MMP-9 inhibitor o-phenanthroline at 100 mg/kg b.w. per day on days 2 and 5 in combination with G-CSF 250 mg/kg b.w per day.
The mice were killed 6 h after the last injection. PB was collected by cardiac aspiration in heparinized tubes. Nucleated cells (2 Â 10 5 per ml) were then seeded for progenitor colony assay with methyl cellulose MethoCultGF M3434 (Stem Cell Technologies Inc., Vancouver, BC, Canada). Myeloid and erythroid colony forming cells (CFC) were scored on 5-7 days by morphologic criteria. BM samples were obtained from femurs, tibias, humeri and pelvis. All of the animal handling and experimental procedures were approved by the Animal Care and Use Committee of CAMS and PUMC.
Statistical analysis
Normally distributed data were expressed as means±s.d.. The statistical significance of overall differences among multiple groups was analyzed by the ordinary analysis of variance using SPSS 10.0. If the test showed a statistical significance, pair-wise comparisons were further performed using the multiple-comparisons criterion. P-values of less than 0.05 were considered statistically significant.
Results

SDF-1 functionally decreased in the BM after 5 days of G-CSF administration
To examine the role of SDF-1 in G-CSF-induced mobilization, SDF-1 protein was determined by ELISA in the plasma of healthy donors before or after 5 days of G-CSF treatment. As shown by others, 3 there was a higher expression level of SDF-1 in BM plasma (7.23 ± 0.66 ng/ml) compared with that of PB (5.43 ± 0.35 ng/ml) in the steady state. After 5 days G-CSF of administration, SDF-1 in the BM plasma decreased to 5.88 ± 1.03 ng/ml (Po0.05), whereas there was no significant change in the PB plasma (4.86±0.52 ng/ml; P40.05). This result was further confirmed by immunohistochemical staining of human BM biopsy slides. High SDF-1 protein was clearly detected on immature osteoblasts lining the steady-state bone endosteum region, whereas SDF-1 was absent on the 5 days of G-CSF-mobilized bone endosteum region (Figure 1) . Therefore, the gradient of SDF-1 from the BM toward the PB disappeared after 5 days of G-CSF administration.
In the subsequent experiment, ssBM and mBM plasma from healthy donors were tested for their chemotactic activity in migration assays; in this assay, CD34 þ cells were placed in the upper chamber of transwell and plasma was placed in the lower one. The chemotactic response of CD34 þ cells decreased from 11.91±0.61% toward ssBM plasma to 10.20 ± 0.29% toward mBM plasma (Po0.05). This is in agreement with the published data. 3 These results showed that G-CSF not only induced a decrease of SDF-1 protein concentration, but also decreased its function. Furthermore, this reduction was not due to the dispersion of this chemokine from BM into PB because no significant change in the PB plasma was observed.
G-CSF transiently upregulated SDF-1 mRNA expression on BM stromal cell and HUVECs SDF-1 is produced and secreted by several nonhematopoietic cell types in the BM stroma, mainly immature osteoblasts, and is expressed by endothelial cells. [26] [27] We SDF-1 and MMP-9 on G-CSF-induced HSPC mobilization F Jin et al examined the potential stimulatory effect of G-CSF on SDF-1 mRNA expression by RT-PCR using human BM stromal cell and HUVECs. It was surprising that G-CSF upregulated SDF-1 mRNA after 24 h treatment, then decreased its expression at 48 h (Figure 2 ), whereas it was very low in untreated human stromal cells and HUVECs.
There was no significant difference between stromal cells and HUVECs. Therefore, the regulation of SDF-1 mRNA by G-CSF is not likely to be the mechanism behind the general decrease of SDF-1 protein seen within the BM.
Proteolytic degradation of BM SDF-1 by MMP-9
The above data showed that despite of the increased SDF-1 mRNA expression, SDF-1 protein in human BM decreased by G-CSF administration without a noticeable increase of this chemokine in the PB. That raises the possibility of SDF-1 protein being degraded in the BM during HSPCs mobilization.
In the process of G-CSF-induced mobilization, another prominent phenomenon was the change of MMP-9 expression. Significant increase of MMP-9 protein (about 6.7-fold) and mRNA (Figure 3a ) in human mBM plasma was observed by ELISA (Po0.01) and RT-PCR. Immunohistology staining of BM sections showed that the MMP-9 expression was clearly detected in the neutrophil cytoplasm after mobilization, whereas only disseminated MMP-9 ( þ ) neutrophils were seen in ssBM section (Figure 3b ).
Is SDF-1 a substrate for MMP-9? After coincubation with MMP-9 for 4-6 h, recombinant SDF-1a decreased from 58.55 ± 0.35 to 40.4 ± 0.71 ng/ml, suggesting SDF-1a was significantly degraded by MMP-9 (Po0.05) whereas anti-MMP-9 MoAb could block this degradation to the level of the control. Likewise, human mBM plasma also had significant SDF-1 proteolytic degradation activity compared with ssBM plasma (Po0.05; Figure 3c ). These data in vitro indicated that MMP-9 could degrade SDF-1 and the proteolytic activity of MMP-9 might be the cause of the SDF-1 concentration decrease during G-CSF mobilization.
Besides neutrophils, hematopoietic stem cells also express MMPs, and their expression may be important in HSPCs in vitro migration through mimic basement membranes. 15, 28 To further investigate the role of MMP-9 in HSPCs mobilization and the relationship between MMP-9 and SDF-1, we tested whether SDF-1 stimulated MMP-9 secretion in the enriched CD34 þ cells from ssBM. As shown in Figure 3d , CD34 þ cells did not secrete MMP-9 protein under the serum-free condition; however, SDF-1 and G-CSF could stimulate these CD34 þ cells to secrete activated MMP-9.
These data demonstrated that SDF-1 is a substrate of MMP-9, and high-level MMP-9 protein could explain the disappearance of SDF-1 gradient between BM and PB during the G-CSF mobilization. Furthermore, SDF-1 and G-CSF could also increase MMP-9 activity of BM CD34 þ cells.
MMP-9 affected CXCR4 expression and the migratory capacity of CD34 þ cells Because G-CSF decreased SDF-1 protein in the BM by proteolytic degradation by MMP-9, we further evaluated whether the expression of CXCR4, the unique receptor of SDF-1, on hematopoietic cells was also affected. In this part, we observed that CXCR4 expression significantly upregulated on mBM CD34 Did MMP-9 lead to the CXCR4 upregulation? We observed that enriched MMP-9 supernatant from human cell line (HT1080) upregulated CXCR4 expression on human ssBM and mPB CD34 þ cells (Po0.05; Figure 4a ). Moreover, it also increased SDF-1-mediated migration ability of these CD34 þ cells (Po0.05), which could be inhibited by MMP inhibitor (MPI), o-phenanthroline (Figure 4b ).
These results indicated CXCR4 expression on HSPCs was regulated by multiple factors, and MMP-9 was at least one of them. Increased chemotactic activity of CD34 þ cells might be another effect of MMP-9 during the G-CSF mobilization.
In vivo MMP-9 inhibitor reduced G-CSF-induced mobilization in mice The role of the BM MMP-9 and SDF-1 gradient during the mobilization process was further tested by injection of anti-SDF-1 MoAb and MMP-9 inhibitor into G-CSF-treated BALB/c mice. Anti-SDF-1 MoAb was injected into BALB/ c mice on days 4 and 5 of mobilization after each G-CSF administration. We observed a decrease of the mobilized hematopoietic cells in the circulation (Po0.05; Figure 5a ). However, there was no significant change in the BM, indicating that the cells remained in the BM and did not egress into circulation.
Furthermore, we also found that MPIs not only inhibited the SDF-1 degradation in BM, but also significantly decreased the number of WBC (14. Taken together, these results suggested that MMP-9-dependent degradation of SDF-1 was an important step in the process of G-CSF administration, which led to hematopoietic cell mobilization.
Discussion
In this study, we demonstrated by ELISA and immunohistology that the gradient of SDF-1 between BM and PB disappeared after 5 days of G-CSF administration. In vitro migration assays and the in vivo neutralizing anti-SDF-1 antibodies further confirmed that SDF-1 protein functionally decreased after G-CSF stimulation, and this decrease might have induced HSPC egress to blood circulation. This is in accordance with other published reports. 6, 7, 29 Increased MMP-9 concentration was also observed in the mBM plasma in this study. With respect to the cleaving role of MMP-9 in SDF-1 degradation, [30] [31] [32] [33] it was further assessed whether SDF-1 was a substrate for MMP-9 in this study. Results showed that recombinant SDF-1 was degraded when preincubated for 4-6 h with MMP-9 in vitro, whereas anti-MMP-9 Ab could restore this degradation to the level of the control. Consistent with this, mBM plasma from healthy donors also had significant SDF-1 proteolytic degradation activity. Furthermore, we also found that MMP inhibitor not only inhibited the SDF-1 degradation in BM, but also significantly decreased the number of WBC and CFC in the BALB/c mice PB. Although other data show that G-CSF-induced HSPC mobilization involves MMP-9, without reversing the positive gradient of SDF-1 between BM and PB, 34 our data suggested that disappearance of SDF-1 between BM and PB was related to the degrading activity of MMP-9, and MMP-9-dependent SDF-1-degradation might be a crucial step in HSPC mobilization.
Although the protein level of SDF-1 decreased in human mBM in vivo, data in vitro showed that SDF-1 mRNA expression in HUVECS and stromal cells was upregulated, then decreased its expression after temporary incubation with G-CSF. One of the explanations is that there is a deviation between SDF-1 protein and mRNA expression. G-CSF regulates SDF-1 expression in the BM not primarily at the mRNA level. Another is that an interaction exists between SDF-1 and MMP-9 expression. We supposed that injection of G-CSF may increase SDF-1 expression in vivo on the first day, then upregulate MMP-9 expression, and in reverse, upregulated MMP-9 gradually degraded SDF-1. Although we did not check the kinetics of SDF-1 due to the difficulty in collection of mBM samples from healthy donors during HSPCs mobilization, Petit's 3 data from mice confirmed this hypothesis. Our work advanced their findings by showing evidence that SDF-1 stimulated MMP-9 secretion in BM CD34 þ cells in vitro, which suggested a possible positive feed back loop between MMP-9 and SDF-1.
SDF-1 receptor-CXCR4 expression is closely related to SDF-1-mediated directional migration, 3, 19, [35] [36] [37] it was also demonstrated that the expression of CXCR4 on mBM CD34 þ cells in healthy donors increased after mobilization in this study. However, CXCR4 expression on BM CD34 þ cells decreased when incubated with G-CSF in vitro. The discrepancy of in vitro and in vivo data indicated that there could be other factors that stimulate CXCR4 expression during G-CSF mobilization. It was observed in our study that MMP-9 enriched HT1080 serum-free supernatant increased CXCR4 expression on enriched CD34 þ cells and SDF-1-mediated migration in vitro, which could be blocked by MMPs inhibitor. The latest data also indicate that MMP-9 is also involved in the lung cancer metastasis through the CXCR4/ERK/NF-kB signal transduction pathway. 38 These data showed an alternative effect of MMP-9 on the CXCR4 expression in the process of G-CSF-induced HSPCs mobilization.
However, we could only suggest one or partial molecular explanation for this mobilized process at the time. Some inconsistent data still existed, for example, SDF-1 Ab or MMP-9 inhibitor could only partially decrease but not completely inhibit the G-CSF mobilization in BLAB/c mice. MMP-9 protein upregulation was also observed in mPB (about 14.5-fold), even higher than that in mBM; however, there was no change of SDF-1 protein between ssPB and mPB. Therefore, SDF-1 gradient disappearance may be multifactorial and not only from the MMP-9 proteolytic activity. Indeed, as reviewed by Papayannopoulou, 39 integrins/ligands and stem cell factor/c-kit may also be involved in mobilization. Another finding from this SDF-1 and MMP-9 on G-CSF-induced HSPC mobilization F Jin et al research was that the number of immature osteoblasts lining the bone endosteal region (near the HSC niche) also diminished significantly after G-CSF mobilization, which is consistent with the recent publications that bone remodeling also plays role in HSPCs mobilization. [40] [41] [42] [43] [44] In conclusion, our study revealed the pivotal role of MMP-9-dependent degradation of SDF-1 in the process of G-CSF-induced HSPCs mobilization. Our group is now evaluating the effect of G-CSF on the osteoblast/osteoclast and the relationship between bone remodeling and the extracellular matrix components (such as SDF-1, MMP-9 and so on) in the HSPCs mobilization. Manipulation of these interactions would lead to new perspectives on the development of improved clinical protocols for stem cell mobilization in poor mobilizers.
